U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07158606) titled 'Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction' on Aug. 28.
Brief Summary: The goal of this clinical trial is to learn how well Altuviiio (efanesoctacog alpha) works for Immune Tolerance Induction (ITI) while using Hemlibra (emicizumab) to prevent bleeds.
Participants will be given Altuviiio for their ITI therapy and also be treated with Hemlibra as standard of care prophylaxis to prevent bleeding. The research doctor will decide how much and how often the participant will get Hemlibra.
Participants will need to attend visits for checkups and tests. These visits are divided into...